Purpose. To clarify the role of perforin-and Fas ligand (L)-mediated cytotoxicity pathogenesis of viral myocarditis. Materials and methods. Forty balb/c mice were randomly divided into experimental group (n = 20) and ...Purpose. To clarify the role of perforin-and Fas ligand (L)-mediated cytotoxicity pathogenesis of viral myocarditis. Materials and methods. Forty balb/c mice were randomly divided into experimental group (n = 20) and control group (n = 20), and inoculated intraperitoneally with coxsackievirus B3(CVB3) and Eagle’s solu- tion without CVB3, respectively. The mice were sacrificed and their hearts were removed at day 7 post-in- oculation. Expression of perform and FasL were detected with immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization. Results. (1)Perform-and FasL-positiye cells were demonstrated in experimental murine hearts by im- munohistochemistry, however, no cells were discovered in control murine hearts; (2) The examination of RT-PCR showed the positive ratios of perform and FasL mRNA in myocardium were significantly higher in experimental group (100% and 100 % ) than that in control group (20% and 30 %, P<0.05); (3)Positive signals of perform and FasL mRNA were found in myocardium of all the experimental mice by in situ hybridization, but nothing was detected in control group. Conclusion. Perform and FasL can be expressed in infiltrating cells in murine myocardium with acute myocarditis caused by CVB3, suggesting perform and FasL might play an important role in pathogenesis of viral myocarditis.展开更多
目的:基于网络药理学与GEO数据库探讨心瘅方治疗病毒性心肌炎的microRNA-mRNA调控机制。方法:使用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)筛选心瘅...目的:基于网络药理学与GEO数据库探讨心瘅方治疗病毒性心肌炎的microRNA-mRNA调控机制。方法:使用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)筛选心瘅方中药物活性成分及其靶基因;利用GEO数据库筛选病毒性心肌炎与健康人的差异microRNA;利用FunRich3.1.3对差异microRNA进行mRNA富集,并与药物靶基因取交集基因;通过蛋白-蛋白互作网络(protein-protein interactions,PPI)以及cytoNCA筛选出核心基因;运用R软件对核心基因进行基因本体(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集分析。结果:心瘅方中药物活性成分共199个,潜在作用靶点490个,GEO数据库Series GSE148153符合要求,通过筛选得到差异microRNA 438个,50个microRNA与核心基因有对应关系,上调基因45个,下调基因5个;筛选得到交集基因207个,其中33个为核心基因;GO功能注释主要富集在肌细胞增殖、MAP激酶活性等生物学过程,并且主要富集在PI3K/Akt、人巨细胞病毒感染、白细胞介素17等信号通路。结论:心瘅方调控microRNA-mRNA过程治疗病毒性心肌炎与中药成分干预肌细胞增殖、MAP激酶活性等生物学过程和PI3K/Akt、人巨细胞病毒感染、肿瘤坏死因子信号通路等有关,此过程可能涉及hsa-miR-15b-5p和hsa-miR-21-5p等外泌体的表达。展开更多
目的:探讨静滴左卡尼汀与cAMP联合治疗病毒性心肌炎(VMC)的具体疗效。方法:选择2020年1月—2022年12月本院收治的64例VMC患者,按随机数字表法分为两组,各32例。对照组予以cAMP注射液40 mg溶于250 ml 5%葡萄糖注射液中静脉滴注,1次/d;观...目的:探讨静滴左卡尼汀与cAMP联合治疗病毒性心肌炎(VMC)的具体疗效。方法:选择2020年1月—2022年12月本院收治的64例VMC患者,按随机数字表法分为两组,各32例。对照组予以cAMP注射液40 mg溶于250 ml 5%葡萄糖注射液中静脉滴注,1次/d;观察组于对照组基础上加用左卡尼汀注射液10~20 mg/kg溶于250 ml 5%葡萄糖注射液中静脉滴注,1次/d。两组持续治疗14 d。比较两组临床疗效、血清炎症因子水平、心肌损伤标志物水平、不良反应。结果:观察组总有效率为96.88%(31/32),显著高于对照组的71.88%(23/32),差异有统计学意义(P<0.05);治疗前,两组白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN-γ)比较,差异无统计学意义(P>0.05),治疗后,观察组IL-4水平较对照组高,IL-6、TNF-α和IFN-γ水平较对照组低,差异有统计学意义(P<0.05);治疗前,两组心肌肌钙蛋白T(c TnT)、肌酸激酶同工酶(CK-MB)和血浆N末端脑钠肽前体(NT-proBNP)比较,差异无统计学意义(P>0.05),治疗后,观察组c TnT、CK-MB和NT-proBNP均低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为15.63%(5/32),与对照组的9.38%(3/32)比较,差异无统计学意义(P>0.05)。结论:VMC患者采用左卡尼汀联合cAMP治疗,可在一定程度上增强患者的临床疗效,进一步缓解炎性反应,减轻心肌损伤,且用药安全性较高。展开更多
文摘Purpose. To clarify the role of perforin-and Fas ligand (L)-mediated cytotoxicity pathogenesis of viral myocarditis. Materials and methods. Forty balb/c mice were randomly divided into experimental group (n = 20) and control group (n = 20), and inoculated intraperitoneally with coxsackievirus B3(CVB3) and Eagle’s solu- tion without CVB3, respectively. The mice were sacrificed and their hearts were removed at day 7 post-in- oculation. Expression of perform and FasL were detected with immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization. Results. (1)Perform-and FasL-positiye cells were demonstrated in experimental murine hearts by im- munohistochemistry, however, no cells were discovered in control murine hearts; (2) The examination of RT-PCR showed the positive ratios of perform and FasL mRNA in myocardium were significantly higher in experimental group (100% and 100 % ) than that in control group (20% and 30 %, P<0.05); (3)Positive signals of perform and FasL mRNA were found in myocardium of all the experimental mice by in situ hybridization, but nothing was detected in control group. Conclusion. Perform and FasL can be expressed in infiltrating cells in murine myocardium with acute myocarditis caused by CVB3, suggesting perform and FasL might play an important role in pathogenesis of viral myocarditis.
文摘目的:基于网络药理学与GEO数据库探讨心瘅方治疗病毒性心肌炎的microRNA-mRNA调控机制。方法:使用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)筛选心瘅方中药物活性成分及其靶基因;利用GEO数据库筛选病毒性心肌炎与健康人的差异microRNA;利用FunRich3.1.3对差异microRNA进行mRNA富集,并与药物靶基因取交集基因;通过蛋白-蛋白互作网络(protein-protein interactions,PPI)以及cytoNCA筛选出核心基因;运用R软件对核心基因进行基因本体(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集分析。结果:心瘅方中药物活性成分共199个,潜在作用靶点490个,GEO数据库Series GSE148153符合要求,通过筛选得到差异microRNA 438个,50个microRNA与核心基因有对应关系,上调基因45个,下调基因5个;筛选得到交集基因207个,其中33个为核心基因;GO功能注释主要富集在肌细胞增殖、MAP激酶活性等生物学过程,并且主要富集在PI3K/Akt、人巨细胞病毒感染、白细胞介素17等信号通路。结论:心瘅方调控microRNA-mRNA过程治疗病毒性心肌炎与中药成分干预肌细胞增殖、MAP激酶活性等生物学过程和PI3K/Akt、人巨细胞病毒感染、肿瘤坏死因子信号通路等有关,此过程可能涉及hsa-miR-15b-5p和hsa-miR-21-5p等外泌体的表达。
文摘目的:探讨静滴左卡尼汀与cAMP联合治疗病毒性心肌炎(VMC)的具体疗效。方法:选择2020年1月—2022年12月本院收治的64例VMC患者,按随机数字表法分为两组,各32例。对照组予以cAMP注射液40 mg溶于250 ml 5%葡萄糖注射液中静脉滴注,1次/d;观察组于对照组基础上加用左卡尼汀注射液10~20 mg/kg溶于250 ml 5%葡萄糖注射液中静脉滴注,1次/d。两组持续治疗14 d。比较两组临床疗效、血清炎症因子水平、心肌损伤标志物水平、不良反应。结果:观察组总有效率为96.88%(31/32),显著高于对照组的71.88%(23/32),差异有统计学意义(P<0.05);治疗前,两组白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN-γ)比较,差异无统计学意义(P>0.05),治疗后,观察组IL-4水平较对照组高,IL-6、TNF-α和IFN-γ水平较对照组低,差异有统计学意义(P<0.05);治疗前,两组心肌肌钙蛋白T(c TnT)、肌酸激酶同工酶(CK-MB)和血浆N末端脑钠肽前体(NT-proBNP)比较,差异无统计学意义(P>0.05),治疗后,观察组c TnT、CK-MB和NT-proBNP均低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为15.63%(5/32),与对照组的9.38%(3/32)比较,差异无统计学意义(P>0.05)。结论:VMC患者采用左卡尼汀联合cAMP治疗,可在一定程度上增强患者的临床疗效,进一步缓解炎性反应,减轻心肌损伤,且用药安全性较高。
